Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)
Yuejie C, Chengyu L, Zhen C, Ching S, Michael H, Munir H, Haskell R, Stefanski K, Qian F
Switching from tirzepatide A growing number of researchers are transitioning from tirzepatide to retatrutide, typically because they have hit a tirzepatide weight loss plateau or want to push past the weight loss ceiling of dual agonism
Mechanisms of natural brassinosteroid-induced apoptosis of prostate cancer cells
Brown Lobbins ML, Scott I-SO, Slominski AT, Hasty KA, Zhang S, Miller DD, et al
